[go: up one dir, main page]

SG10201606654XA - Production cell line enhancers - Google Patents

Production cell line enhancers

Info

Publication number
SG10201606654XA
SG10201606654XA SG10201606654XA SG10201606654XA SG10201606654XA SG 10201606654X A SG10201606654X A SG 10201606654XA SG 10201606654X A SG10201606654X A SG 10201606654XA SG 10201606654X A SG10201606654X A SG 10201606654XA SG 10201606654X A SG10201606654X A SG 10201606654XA
Authority
SG
Singapore
Prior art keywords
cell line
production cell
line enhancers
enhancers
production
Prior art date
Application number
SG10201606654XA
Other languages
English (en)
Inventor
Gang Chen
Darya Burakov
Dipali Deshpande
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG10201606654XA publication Critical patent/SG10201606654XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2477—Hemicellulases not provided in a preceding group
    • C12N9/2488—Mannanases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG10201606654XA 2012-05-29 2013-05-29 Production cell line enhancers SG10201606654XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261652549P 2012-05-29 2012-05-29
US13/904,587 US9079954B2 (en) 2012-05-29 2013-05-29 Production cell line enhancers

Publications (1)

Publication Number Publication Date
SG10201606654XA true SG10201606654XA (en) 2016-10-28

Family

ID=49670701

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201407652RA SG11201407652RA (en) 2012-05-29 2013-05-29 Production cell line enhancers
SG10201606654XA SG10201606654XA (en) 2012-05-29 2013-05-29 Production cell line enhancers

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201407652RA SG11201407652RA (en) 2012-05-29 2013-05-29 Production cell line enhancers

Country Status (20)

Country Link
US (9) US9079954B2 (fr)
EP (3) EP2875047B1 (fr)
JP (5) JP6298455B2 (fr)
KR (4) KR102126210B1 (fr)
CN (2) CN104350068B (fr)
AU (4) AU2013267525B2 (fr)
BR (1) BR112014029095A2 (fr)
CA (1) CA2873131A1 (fr)
DK (1) DK2875047T5 (fr)
EA (2) EA201792213A1 (fr)
ES (1) ES2940900T3 (fr)
FI (1) FI2875047T3 (fr)
HU (1) HUE061479T2 (fr)
IL (4) IL320011A (fr)
MX (1) MX360359B (fr)
PL (1) PL2875047T3 (fr)
SG (2) SG11201407652RA (fr)
TW (2) TWI641687B (fr)
WO (1) WO2013181253A1 (fr)
ZA (1) ZA201408289B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI641687B (zh) 2012-05-29 2018-11-21 美商再生元醫藥公司 生產細胞株增強子
US11530277B2 (en) 2016-04-20 2022-12-20 Regeneron Pharmaceuticals, Inc. Compositions and methods for making antibodies based on use of an expression-enhancing locus
IL314779A (en) 2016-04-20 2024-10-01 Regeneron Pharma Compositions and methods for making antibodies based on use of expression-enhancing loci
PL3532497T3 (pl) * 2016-10-26 2024-11-04 The Board Of Trustees Of The Leland Stanford Junior University Zmodyfikowane regiony zawiasowe immunoglobuliny dla zmniejszania hemaglutynacji
JP7116059B2 (ja) 2016-11-21 2022-08-09 ジャスト－エヴォテック バイオロジックス、インコーポレイテッド アフリベルセプト製剤及びその使用
MY199833A (en) 2017-08-17 2023-11-24 Just Evotec Biologics Inc Method of purifying glycosylated protein from host cell galectins and other contaminants
JP7183268B2 (ja) 2017-11-20 2022-12-05 ジャスト－エヴォテック バイオロジックス、インコーポレイテッド 等張化剤としてリジン塩を含有するアフリベルセプト製剤及びその使用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002057423A2 (fr) 2001-01-16 2002-07-25 Regeneron Pharmaceuticals, Inc. Isolement de cellules exprimant des protéines sécrétées
WO2003101189A1 (fr) 2002-05-29 2003-12-11 Regeneron Pharmaceuticals, Inc. Systeme d'expression eucaryote inductible
AU2003268356A1 (en) 2002-08-30 2004-03-19 President And Fellows Of Harvard College Methods and compositions for modulating xbp-1 activity
CA2528418A1 (fr) 2003-06-11 2004-12-23 Biogen Idec Ma Inc. Procede d'accroissement de la production en culture de proteines
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
DK2339015T3 (en) * 2004-03-31 2018-08-06 Janssen Biotech Inc Methods for changing protein production rates
KR20070061524A (ko) * 2004-07-20 2007-06-13 제넨테크, 인크. 안지오포이에틴-유사 4 단백질을 사용하는 조성물 및 방법
AU2005282746A1 (en) 2004-09-02 2006-03-16 Wyeth Systems and methods for protein production
CN101056656A (zh) * 2004-09-15 2007-10-17 哈佛大学校长及研究员协会 在治疗肥胖症和糖尿病中降低er应力
EP1964922A1 (fr) * 2007-03-02 2008-09-03 Boehringer Ingelheim Pharma GmbH & Co. KG Amélioration de production de protéine
US8546126B2 (en) 2007-03-21 2013-10-01 Danisco Us Inc. Over expression of foldases and chaperones improves protein production
EP2150617B1 (fr) 2007-06-04 2014-10-22 Regeneron Pharmaceuticals, Inc. Régions d'expression et de stabilité amplifiées
WO2009020802A2 (fr) * 2007-08-03 2009-02-12 Eli Lilly And Company Traitement de l'obésité
PE20091163A1 (es) * 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
US20110281301A1 (en) 2007-11-13 2011-11-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg The secretory capacity in host cells
US20090247609A1 (en) * 2007-12-20 2009-10-01 Hitto Kaufmann Sm-protein based secretion engineering
JP5694924B2 (ja) 2008-05-28 2015-04-01 バイエル・ヘルスケア・エルエルシー ＨＢｘ発現哺乳動物細胞における組み換えタンパク質の製造方法およびその組成物
US20110142799A1 (en) 2008-06-23 2011-06-16 President And Fellows Of Harvard College Modulation of neurodegenerative disease by modulating xbp-1 activity
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
GB0902180D0 (en) * 2009-02-10 2009-03-25 Ucb Pharma Sa Method for producing protein
US8722046B2 (en) * 2009-04-08 2014-05-13 The United States Of America As Represented By The Secretary Of The Army Human monoclonal antibodies protective against bubonic plague
ES2527173T3 (es) 2009-06-02 2015-01-21 Regeneron Pharmaceuticals, Inc. Células de fucosilación deficiente
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
JO3274B1 (ar) 2009-12-24 2018-09-16 Regeneron Pharma أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
TWI641687B (zh) 2012-05-29 2018-11-21 美商再生元醫藥公司 生產細胞株增強子
EP2914278B1 (fr) 2012-11-05 2021-06-02 Dana-Farber Cancer Institute, Inc. Xbp1, cd138 et cs1, compositions pharmaceutiques qui comprennent les peptides et procédés d'utilisation de tels peptides et compositions

Also Published As

Publication number Publication date
BR112014029095A2 (pt) 2017-07-18
AU2018201094A1 (en) 2018-03-15
JP2018108094A (ja) 2018-07-12
US10611831B2 (en) 2020-04-07
KR20230065370A (ko) 2023-05-11
KR20200074273A (ko) 2020-06-24
AU2021240303B2 (en) 2025-02-27
TW201402815A (zh) 2014-01-16
AU2018201094B2 (en) 2019-06-20
US20160304598A1 (en) 2016-10-20
SG11201407652RA (en) 2014-12-30
JP2022044609A (ja) 2022-03-17
EP4219546A3 (fr) 2023-08-23
EP4219546A2 (fr) 2023-08-02
TW201823460A (zh) 2018-07-01
CN110835624A (zh) 2020-02-25
CA2873131A1 (fr) 2013-12-05
IL235573B (en) 2019-09-26
US20150299309A1 (en) 2015-10-22
US9382315B2 (en) 2016-07-05
KR102528950B1 (ko) 2023-05-08
US10227401B2 (en) 2019-03-12
JP2020022514A (ja) 2020-02-13
JP7382383B2 (ja) 2023-11-16
MX2014014630A (es) 2015-02-12
KR20220003165A (ko) 2022-01-07
EP3564262A1 (fr) 2019-11-06
DK2875047T3 (da) 2023-03-27
US9079954B2 (en) 2015-07-14
FI2875047T3 (fi) 2023-03-30
JP2023153268A (ja) 2023-10-17
EA201792213A1 (ru) 2018-01-31
AU2013267525A1 (en) 2014-12-11
US20150175688A1 (en) 2015-06-25
AU2019203780A1 (en) 2019-06-20
AU2019203780B2 (en) 2021-07-01
US20190270800A1 (en) 2019-09-05
JP2015518728A (ja) 2015-07-06
ES2940900T3 (es) 2023-05-12
IL279922B1 (en) 2025-05-01
CN104350068B (zh) 2019-12-03
AU2013267525B2 (en) 2017-11-16
KR102346867B1 (ko) 2022-01-04
JP6622334B2 (ja) 2019-12-18
AU2021240303A1 (en) 2021-10-28
US20170291938A1 (en) 2017-10-12
JP7037535B2 (ja) 2022-03-16
US9193786B2 (en) 2015-11-24
DK2875047T5 (da) 2024-10-14
IL265867A (en) 2019-06-30
WO2013181253A1 (fr) 2013-12-05
HK1205137A1 (en) 2015-12-11
HUE061479T2 (hu) 2023-07-28
US20150299310A1 (en) 2015-10-22
KR102126210B1 (ko) 2020-06-25
EP2875047B1 (fr) 2023-01-25
IL279922B2 (en) 2025-09-01
IL320011A (en) 2025-06-01
IL279922A (en) 2021-03-01
IL235573A0 (en) 2015-01-29
ZA201408289B (en) 2016-09-28
KR102663134B1 (ko) 2024-05-03
EA028790B1 (ru) 2017-12-29
PL2875047T3 (pl) 2023-05-29
TWI641687B (zh) 2018-11-21
US20150353634A1 (en) 2015-12-10
US10351622B2 (en) 2019-07-16
US20130323788A1 (en) 2013-12-05
KR20150015492A (ko) 2015-02-10
MX360359B (es) 2018-10-30
USRE48651E1 (en) 2021-07-20
CN104350068A (zh) 2015-02-11
US9688751B2 (en) 2017-06-27
JP6298455B2 (ja) 2018-03-20
US9228012B2 (en) 2016-01-05
EA201492242A1 (ru) 2015-05-29
EP2875047A1 (fr) 2015-05-27

Similar Documents

Publication Publication Date Title
SG11201502216UA (en) Cell lines
GB201301173D0 (en) Object production
GB201213832D0 (en) Cathode
AU347859S (en) Battery
AU346864S (en) Battery
EP2815546A4 (fr) Construction d'un dvpn à grande échelle
SG11201503579RA (en) Cell culture med
SG10201700670WA (en) Cell culture
GB2513756B (en) Anaerobic process
IL265867A (en) Amplifiers of production cell lines
EP2898114A4 (fr) Production d'hydrogène
AU2013200983B9 (en) Hydrogen production
SG11201405540QA (en) A cell arrangement
EP2835852A4 (fr) Pile à combustible
EP2830130A4 (fr) Pile à combustible
EP2904852A4 (fr) Découverte d'une petite cellule
EP2939294A4 (fr) Batterie
EP2882020A4 (fr) Pile à combustible
GB201211873D0 (en) Cell culture
GB201218280D0 (en) Photovoltaic cell
GB201218045D0 (en) Battery
GB201104761D0 (en) Biodiesel production
EP2808929A4 (fr) Pile à combustible
EP2804245A4 (fr) Pile à combustible
GB201218496D0 (en) Cell